John Pajka, MD
Ophthalmology · Lima, OHNPI 1861469108
Payments from drug & device makers
What this record shows
This record is dominated by charitable contributions: $3,400 of the $4,516 with a category attached, or 75.3%. Microsurgical Technology, Inc. accounts for 75.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $3,819 and has fallen 92.7% since, to $280 in 2025.
Across 20 payments — averaging $225.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Microsurgical Technology, Inc.$3K
- AbbVie$297
- Alcon$176
- Johnson & Johnson Surgical Vision, Inc.$164
- Bausch & Lomb Americas Inc.$149
- Carl Zeiss Meditec USA, Inc.$149
- plus $180 from 2 others
Across 7 payments — averaging $2,524,677 each. An ownership or investment interest held by the physician or an immediate family member.
- Midmark Corporation$17.7M
What the payments were for
- Food & beverage$1,11625%
- Charitable contribution$3,40075%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Microsurgical Technology, Inc. | 2 | $3,400 |
| AbbVie(2 entities) | 5 | $297 |
| Alcon | 3 | $176 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $164 |
| Bausch & Lomb Americas Inc. | 2 | $149 |
| Carl Zeiss Meditec USA, Inc. | 1 | $149 |
| Rxsight Inc | 1 | $120 |
| Carl Zeiss Meditec, Inc. | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,516 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 825 | $51,169 |
| MoxifloxacinMoxifloxacin Hcl | 585 | $20,633 |
| Timolol Maleate | 156 | $1,081 |
| Latanoprost | 134 | $1,010 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $617 |
| Dorzolamide Hcl | 17 | $354 |
| Ofloxacin | 21 | $246 |
| Tobramycin | 24 | $206 |
| Brimonidine Tartrate | 18 | $196 |
| Ketorolac Tromethamine | 13 | $139 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Lima
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
- Justis EhlersCleveland$639K
- Lawrence SingermanBeachwood$599K
- Darrell WhiteWestlake$587K
- Alice EpitropoulosColumbus$531K
- Amy MillerDayton$526K
- Sunil SrivastavaCleveland$508K
- William WileyCleveland$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.